AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35450679
Drug: Unplanned DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unplanned DAPT discontinuation ≥3 weeks after PCI
Trial: 35450679
Drug: Planned DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned DAPT discontinuation
Trial: 35450750
Drug: On-treatment low-density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-treatment low-density lipoprotein cholesterol (LDL-C)
Trial: 35450817
Drug: Low-intensity chemotherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity chemotherapy
Trial: 35451010
Drug: Endoluminal vacuum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoluminal vacuum therapy (EVT) using Eso-Sponge®
Trial: 35451176
Drug: Voxelotor treatment
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Voxelotor treatment for up to 48 weeks
Trial: 35452178
Drug: Newer disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer disease-modifying therapies being developed and studied
Trial: 35452519
Drug: Leronlimab (CCR5-binding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (CCR5-binding antibody), specific dosage and duration not mentioned
Trial: 35453064
Drug: Perampanel (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (median maximum dose 6.0 mg/day)
Trial: 35454839
Drug: Noninvasive physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive physical plasma (NIPP) treatment
Trial: 35454839
Drug: NIPP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPP treatment
Trial: 35455660
Drug: Intravenous antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antiarrhythmic agents (amiodarone, vernakalant, ibutilide)
Trial: 35456277
Drug: Neurological music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological music therapy for 3 months
Trial: 35460043
Drug: Lixisenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (10 μg sc)
Trial: 35460313
Drug: Pain management
RxNorm normalized name: Olu Pain Management 4%-1% Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain management at haemophilia treatment centres (HTC)
Trial: 35460313
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of depression/anxiety at haemophilia treatment centres (HTC)
Trial: 35460412
Drug: Ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian stimulation during IUI treatment
Trial: 35460497
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI; Acthar® Gel); 80 U subcutaneously twice weekly for 12 weeks
Trial: 35460976
Drug: Gamma-secretase inhibitor
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-secretase inhibitor AL102
Trial: 35460976
Drug: Beta-catenin inhibitor
RxNorm normalized name: cefpodoxime and beta-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-catenin inhibitor Tegavivint (BC2059)
Trial: 35461262
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) scopolamine administered over the course of 2 weeks with three blinded infusions.
Trial: 35461262
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered over the course of 2 weeks with three blinded infusions.
Trial: 35463939
Drug: Effective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective treatment (including rescue FMT)
Trial: 35465706
Drug: Artemisinin-naphthoquine (ART-NQ)
RxNorm normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-naphthoquine (ART-NQ) single doses of 20 mg/kg for artemisinin and 8 mg/kg for naphthoquine.
Trial: 35466039
Drug: One antipseudomonal
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One antipseudomonal class (e.g., beta-lactam)
Trial: 35466039
Drug: Two antipseudomonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two antipseudomonal classes (e.g., beta-lactam/aminoglycoside)
Trial: 35466039
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more antipseudomonal classes (e.g., beta-lactam/aminoglycoside/fluoroquinolone)
Trial: 35466524
Drug: ADI-PEG20 (pegargiminase)
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADI-PEG20 (pegargiminase) combined with pemetrexed (500 mg/m²) and cisplatin (dosage not specified)
Trial: 35467243
Drug: Eftozanermin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eftozanermin alfa (eftoza) 2.5-15 mg/kg intravenously on day 1 or day 1/day 8 every 21 days (dose-escalation phase)
Trial: 35467243
Drug: Eftozanermin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eftozanermin alfa (eftoza) 1.25-7.5 mg/kg once-weekly (QW) (dose-optimization phase)
Trial: 35467749
Drug: Selumetinib at
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib at 25 mg/m2 orally twice daily
Trial: 35468336
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of BNT162b2 vaccine
Trial: 35468336
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of BNT162b2 vaccine
Trial: 35468690
Drug: Cultured autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultured autologous bone marrow MSCs matrix (CC group)
Trial: 35469288
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab
Trial: 35469288
Drug: Combined intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab and suprachoroidal injection of triamcinolone acetonide (4mg/0.1mL)
Trial: 35469443
Drug: Intravenous fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosphenytoin plus oral tapering of phenytoin
Trial: 35469846
Drug: VAS2870 (NADPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAS2870 (NADPH oxidase inhibitor)
Trial: 35469846
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antioxidant treatment)
Trial: 35470225
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate 30 mg plus meloxicam 30 mg
Trial: 35470855
Drug: High consumption
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High consumption of ultra-processed foods (721 ± 341 g/d, 28% of total food intake)
Trial: 35471240
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily activities without modification)
Trial: 35472295
Drug: New Covid-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Covid-19 vaccines
Trial: 35472295
Drug: Active controls
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active controls (existing vaccines)
Trial: 35473396
Drug: Thyroid-Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid-Stimulating Hormone and Thyroid Hormones
Trial: 35473676
Drug: Beta-blockers (prescribed)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (prescribed)
Trial: 35473676
Drug: Beta-blockers (unprescribed)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (unprescribed)
Trial: 35473709
Drug: Il-6 inhibitors
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Il-6 inhibitors and monoclonal antibodies
Trial: 35473709
Drug: Specific antiviral
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific antiviral therapies
Trial: 35473726
Drug: CL2020 cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CL2020 cells (1.5 million cells for low-dose cohort, 15 million cells for high-dose cohort)
Trial: 35475157
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg/day) + ADT
Trial: 35475157
Drug: Flutamide (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (375 mg/day) + ADT
Trial: 35475300
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (DPNB with ropivacaine + tetracaine gel)
Trial: 35475300
Drug: Tetracaine gel
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracaine gel group (DPNB with saline)
Trial: 35475789
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial alternating current stimulation with cognitive treatment
Trial: 35475885
Drug: Treg DLI
RxNorm normalized name: DLin-MC3-DMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treg DLI plus low-dose interleukin-2 (LD IL-2)
Trial: 35475910
Drug: IL-15 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-15 (0.5, 1, and 2 μg/kg subcutaneously 5 days per week for 2 weeks)
Trial: 35475982
Drug: Simulation-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation-based training (40-minute immersive individual simulation training focusing on high-risk medications in older adults)
Trial: 35476127
Drug: WT1 recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1 recombinant protein vaccination (WT1-A10) with vaccine adjuvant AS01
Trial: 35476252
Drug: Antiestrogen hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiestrogen hormonal therapy
Trial: 35476550
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy for ER+/Basal tumors (15% of ER+, HER2- tumors reclassified by 80-GS)
Trial: 35476550
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy for ER+/Luminal subtype
Trial: 35477175
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Hydroxyurea (HU) and thalidomide for 6 months
Trial: 35477380
Drug: HIP-REP intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIP-REP intervention based on Activity of Daily Living
Trial: 35477725
Drug: MAD0004J08 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD0004J08 (single dose via intramuscular injection)
Trial: 35478081
Drug: Composite comparator
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite comparator (LAMA/LABA therapies)
Trial: 35478711
Drug: CCCG-LBL-2016 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCCG-LBL-2016 regimen combined with dasatinib and prophylactic intrathecal infusion
Trial: 35478711
Drug: BCR-ABL tyrosine
RxNorm normalized name: BCR-ABL tyrosine kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCR-ABL tyrosine kinase inhibitor (TKI) dasatinib
Trial: 35482408
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy with highly neutralizing plasma
Trial: 35482408
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy with high neutralizing antibodies
Trial: 35482538
Drug: Blinatumomab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (15 μg/m)
Trial: 35482910
Drug: TETA-2HCl treatment
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA-2HCl treatment
Trial: 35484319
Drug: Recommended dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dose of 15 mg/kg every 2 weeks for patients aged < 12 years or weighing < 40 kg
Trial: 35484319
Drug: Recommended adult
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended adult flat dose of 800 mg every 2 weeks for patients aged ≥ 12 years and weighing ≥ 40 kg
Trial: 35484649
Drug: Itolizumab (anti-CD6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itolizumab (anti-CD6 monoclonal antibody)
Trial: 35484817
Drug: Twice-daily enoxaparin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily enoxaparin (initial dose: 0.5mg/kg per dose; max: 60mg; target anti-Xa activity: 0.20-0.49IU/mL)
Trial: 35486436
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (control)
Trial: 35486475
Drug: Midostaurin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin plus intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and 1-year midostaurin maintenance therapy
Trial: 35486475
Drug: Midostaurin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin plus intensive chemotherapy
Trial: 35486638
Drug: Lurbinectedin 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks
Trial: 35487733
Drug: Polypharmacy (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (defined as the concomitant use of five or more medications, excluding vitamins or dietary supplements)
Trial: 35487814
Drug: 9-valent human
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent human papillomavirus vaccine (9vHPV)
Trial: 35487845
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (SC trastuzumab) administered every 3 weeks for 18 cycles as adjuvant therapy
Trial: 35487845
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab with no chemotherapy
Trial: 35487845
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab with concurrent chemotherapy
Trial: 35487845
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab with sequential chemotherapy
Trial: 35487894
Drug: Wheelchair-modified ergometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheelchair-modified ergometer rowing exercise (REMW), 3 times weekly for up to 30 minutes per session
Trial: 35488337
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids plus long-acting beta agonists
Trial: 35488900
Drug: Glasdegib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib (100 mg once daily) + azacitidine
Trial: 35489133
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug use
Trial: 35489233
Drug: Regorafenib (REGO)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib (REGO) 160 mg/day for 21 days of a 28-day cycle
Trial: 35489377
Drug: Dolutegravir dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir dispersible tablets (5 mg)
Trial: 35491511
Drug: STAR-OX40 T-cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAR-OX40 T-cell therapy
Trial: 35491519
Drug: Low-dose glibenclamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glibenclamide
Trial: 35492329
Drug: Low Fat-Free
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Fat-Free Muscle Index (L-FFMI)
Trial: 35492329
Drug: Large Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large Total Cross-Sectional Spontaneous Portosystemic Shunt Area (L-TSA)
Trial: 35492329
Drug: Simultaneous presence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous presence of L-FFMI and L-TSA
Trial: 35492329
Drug: L-FFMI
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-FFMI
Trial: 35492329
Drug: L-TSA
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TSA
Trial: 35492873
Drug: AXL targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXL targeting intervention, details on dosage and duration not available
Trial: 35492875
Drug: CCL18 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCL18 treatment
Trial: 35493124
Drug: Bamlanivimab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (700 mg) and Etesevimab (1400 mg)
Trial: 35493516
Drug: PF-06671008 (1.5-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06671008 (1.5-400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle
Trial: 35493739
Drug: Microbial samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial samples from the oral cavity, sputum, and ileum of patients with CD
Trial: 35493739
Drug: Oral cavity
RxNorm normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cavity and sputum microbiota
Trial: 35493739
Drug: Microbiota composition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiota composition in oral cavity and sputum
Trial: 35493739
Drug: Microbiota architecture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiota architecture in oral cavity, sputum, and ileum
Trial: 35496758
Drug: rHIgM22 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHIgM22 (0.5 or 2.0 mg/kg)
Trial: 35497778
Drug: Clazakizumab 25
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 25 mg subcutaneously (s.c.) monthly for 12 months
Trial: 35497778
Drug: Clazakizumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab treatment
Trial: 35498381
Drug: Camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab plus low-dose apatinib
Trial: 35499083
Drug: Hymecromone 1200
RxNorm normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hymecromone 1200 mg/d
Trial: 35499083
Drug: Hymecromone 2400
RxNorm normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hymecromone 2400 mg/d
Trial: 35499083
Drug: Hymecromone 3600
RxNorm normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hymecromone 3600 mg/d
Trial: 35499083
Drug: Hymecromone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hymecromone (all doses combined)
Trial: 35499104
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg/day, increased to 20 mg/day after 1 week
Trial: 35499706
Drug: IL-6 treatment
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 treatment on bystander COLO205 cells
Trial: 35499827
Drug: Nonoperative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative management with antibiotics
Trial: 35500016
Drug: Bexmarilimab (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexmarilimab (humanized IgG4 antibody against Clever-1)
Trial: 35500404
Drug: E7389-LF 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389-LF 2.0 mg/m
Trial: 35500404
Drug: E7389-LF 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389-LF 2.0 mg/m with prophylactic pegfilgrastim
Trial: 35501102
Drug: Plasma (P)-myoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma (P)-myoglobin and P-creatine phosphokinase analyzed at 6-hourly intervals after admission for 48 hours and after surgical fixation or fasciotomy for 24 hours.